Novo Nordisk Taps Anthropic’s Claude Science To Speed Up Drug Discovery — Here’s Everything Investors Need To Know
Novo will use Anthropic’s Claude Science in R&D to tackle scientific and drug discovery challenges, aiming to develop new medicines faster.
Stocktwits
More News
NVO To Present Fresh Data From Blockbuster Wegovy Pill At European Conference As Rival Eli Lilly Readies Its Own Obesity Updates
Novo said it will present 44 abstracts at the European Association for the Study of Diabetes symposium later this month.
Stocktwits
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.read more...
Benzinga
From Novo Nordisk to 'Novo': A Strategic Reset Amid Rising Lilly Pressure
From Novo Nordisk to 'Novo': A Strategic Reset Amid Rising Lilly Pressure...
Yahoo! Finance: News
Eli Lilly To Present Fresh Data On Foundayo, Retatrutide In Europe – Here’s Why Berenberg Sees A 21% Potential Upside In LLY Stock
Berenberg sees potential upside to Lilly’s full-year 2026 revenue forecast, which ranges from $85 billion to $87 billion.
Stocktwits
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsNovo Nordisk continues to dominate the global diabetes and obesity care markets with its portfolio of blockbuster GLP-1 therapies...
Nasdaq News: Markets
Can Viking Therapeutics Beat Big Pharma With Monthly Weight-Loss Shots? Here’s The Risk CEO Says Could Derail It
CEO Brian Lian said monthly VK2735 must preserve weight loss without restarting nausea, vomiting and other gastrointestinal effects.
Stocktwits
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
Zacks
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks
Novo Nordisk Just Dropped 'Nordisk' From Its Name as Obesity Drug Battle With Eli Lilly Heats Up Here's Why
Novo Nordisk rebrands as 'Novo' as it seeks to regain obesity drug market share and unveils a new corporate culture.read more...